Home > Investors
Investor Relations Home
E-mail Page Print Page RSS Feeds E-mail Alerts IR Contacts Financial Tear Sheet 
About Us
Download Documentation 2016 Guidance Worksheet
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation Update on ABP-700
Download Documentation ALN-PCSsc Phase 1 Clinical Results Presentation
Download Documentation ABP-700 & MDCO-216 Conference Call Presentation
Corporate Profile
The Medicines Company provides medical solutions to improve health outcomes for patients in acute and intensive care hospitals worldwide. These solutions comprise medicines and knowledge that directly impact the survival and well-being of critically ill patients.
Stock Quote
MDCO (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.18 (0.49%)
Data as of 10/21/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent News
10/18/16The Medicines Company Announces Positive Top-Line Results from Day 90 Interim Analysis in Ongoing ORION-1 Phase 2 Study of PCSK9si
— Compelling efficacy and safety data from ORION-1 interim analysis confirm results up to Day 90 from PCSK9si Phase 1 study and significantly exceed ORION-1 study objectives — — PCSK9si again demonstrated significant and durable LDL-C reduction-with even greater statistical robustness-reaffirming triannual and potentially biannual dosing regimen — — PCSK9si continues to demonstrate high standards of safety and tolerability— ... 
Printer Friendly Version
10/17/16The Medicines Company to Announce Third Quarter Financial Results on October 26, 2016
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 17, 2016-- The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for October 26, 2016 at 8:30 a.m., Eastern Daylight Time, to discuss third-quarter financial results and operational developments. The conference call will be available via phone and webcast. The dial-in information to access the call is: U.S./Canada: ... 
Printer Friendly Version
10/17/16The Medicines Company’s Infectious Disease Portfolio Featured in 16 Presentations at IDWeek 2016
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 17, 2016-- The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and product candidates will be featured in 16 presentations at IDWeek 2016, to be held October 26-30, 2016, in New Orleans. The Company will present data from the Phase 3 TANGO 1 clinical trial of its investigational antibiotic, Carbavance® (meropenem-vaborbactam), in the treat... 
Printer Friendly Version
10/13/16The Medicines Company to Present Data from its Investigational Anesthetic MDCO-700 at the ANESTHESIOLOGY® 2016 Annual Meeting and the ISAP 25th Annual Meeting
—Data from five abstracts include Phase I and preclinical animal studies accepted as oral and poster presentations— —VERONA Phase II clinical development program underway in The Netherlands— PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 13, 2016-- The Medicines Company (NASDAQ:MDCO) today announced that five abstracts with data from its investigational anesthetic MDCO-700 (formerly, ABP-700) development program will be presented at AN... 
Printer Friendly Version
Upcoming Events
10/26/16 8:30 a.m. ET
Q3 2016 The Medicines Company Earnings Conference Call

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.